Advancing Innovation in Rare Cancers

At TargetCancer Foundation, we believe everyone diagnosed with a rare cancer should have effective treatments and a chance to live.

Breaking Down Barriers in Rare Cancer Research Since 2009

TargetCancer Foundation works to advance the development of more effective and personalized treatments for people with rare cancers.

We do this by

Driving

innovative research

Connecting

the rare cancer community

Empowering

people with rare cancers

TargetCancer Foundation’s impact goes beyond the numbers.

Launched

1st

fully-remote precision medicine clinical trial for rare cancer

Enrolling

400

people with rare cancers in TCF-001 TRACK trial

Convened

Thousands

of rare cancer experts through TCF’s scientific meetings

Dedicated

15+ years

and millions of dollars to drive advances in rare and under-resourced cancers

Co-creating New Rare Cancer Tools and Pathways for Discovery

We convene and collaborate with key stakeholders, both organizations and individuals, to advance our shared goal of more effective and personalized treatments for everyone living with rare cancers.

People with rare cancers
and their loved ones

Researchers
studying rare cancers

Companies
developing new drugs and treatments

Advocacy organizations
offering condition-specific support

Medical professionals
caring for rare cancer patients

Government
regulators and policymakers

Precision Medicine Clinical Trial for Rare Cancers

TCF-001 TRACK is an innovative clinical trial enrolling 400 patients with rare cancers or cancer of unknown primary. Through a remote consenting process, patients can fully enroll in the TRACK study from their homes, without traveling to a clinical trial site.

Latest News

The team at TargetCancer has walked this path. They know, intimately, what families and researchers are going through, and they act as binders, bringing together the heavy hitters in science with families to operationalize medical progress.

Abby L.

Volunteer and TCF Community Member

Help us expand treatment options for everyone affected by a rare cancer.